Insider Selling: Nkarta (NASDAQ:NKTX) President Sells 5,649 Shares of Stock

Nkarta, Inc. (NASDAQ:NKTX) President Nadir Mahmood sold 5,649 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $2.07, for a total value of $11,693.43. Following the completion of the transaction, the president directly owned 167,727 shares of the company’s stock, valued at approximately $347,194.89. This trade represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Nkarta Price Performance

NASDAQ NKTX remained flat at $2.04 during mid-day trading on Tuesday. 357,832 shares of the company were exchanged, compared to its average volume of 794,083. Nkarta, Inc. has a 1 year low of $1.31 and a 1 year high of $2.74. The firm has a market capitalization of $144.90 million, a PE ratio of -1.48 and a beta of 0.60. The firm’s fifty day simple moving average is $1.88 and its two-hundred day simple moving average is $2.03.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings data on Monday, November 10th. The company reported ($0.29) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. On average, analysts forecast that Nkarta, Inc. will post -1.7 EPS for the current fiscal year.

Analyst Ratings Changes

NKTX has been the topic of a number of research analyst reports. Stifel Nicolaus decreased their price target on shares of Nkarta from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, November 11th. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nkarta in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Nkarta currently has a consensus rating of “Moderate Buy” and an average price target of $13.25.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NKTX. Savant Capital LLC acquired a new stake in Nkarta during the 2nd quarter valued at approximately $36,000. SG Americas Securities LLC lifted its stake in Nkarta by 35.0% in the third quarter. SG Americas Securities LLC now owns 23,663 shares of the company’s stock valued at $49,000 after buying an additional 6,141 shares during the last quarter. Bailard Inc. bought a new stake in Nkarta in the 3rd quarter valued at about $61,000. CWM LLC boosted its position in shares of Nkarta by 23.4% during the second quarter. CWM LLC now owns 34,758 shares of the company’s stock worth $58,000 after buying an additional 6,601 shares during the period. Finally, Forefront Analytics LLC grew its stake in shares of Nkarta by 41.0% in the third quarter. Forefront Analytics LLC now owns 39,452 shares of the company’s stock worth $82,000 after purchasing an additional 11,473 shares in the last quarter. 80.54% of the stock is currently owned by hedge funds and other institutional investors.

Nkarta Company Profile

Nkarta, Inc is a clinical-stage biotechnology company specializing in the development of off-the-shelf natural killer (NK) cell therapies for the treatment of cancer. Leveraging proprietary activation and expansion technologies, Nkarta aims to harness the innate tumor-killing properties of NK cells while incorporating targeted immuno-engineering approaches to enhance safety, potency and persistence in patients. The company’s platform supports both allogeneic cell manufacturing and genetic modifications to generate chimeric antigen receptor-expressing NK cell candidates designed to address a range of hematologic and solid tumors.

Nkarta’s lead program, NKX019, is an anti-CD19 CAR-NK cell therapy in early-phase clinical trials for relapsed or refractory B-cell malignancies.